Dive Into Dollar Tr...
Health Care: Drugs
Seattle Genetics Inc. (SGEN: NASDAQ)
$36.70 0.38 | 1.05%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 210.81M | 94.78M | 107.47M | 51.96M |
| Cost of Sales | 4.74M | 3.12M | 0.00 | -6.88M |
| Gross Operating Profit | 206.08M | 91.66M | 107.47M | 58.85M |
| Selling, General, and Administrative Expenses | 84.30M | 72.66M | 29.26M | 17.68M |
| Research & Development | 170.30M | 163.40M | 146.41M | 119.14M |
| Operating Income before D & A (EBITDA) | -48.52M | -144.39M | -68.20M | -77.98M |
| Depreciation & Amortization | 8.73M | 16.64M | 6.99M | 6.88M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | 3.47M | -7.64M | 1.93M | 3.17M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -53.78M | -168.67M | -73.26M | -81.68M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -53.78M | -168.67M | -73.26M | -81.68M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -53.78M | -152.03M | -66.26M | -81.68M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -53.78M | -152.03M | -66.26M | -81.68M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -53.78M | -152.03M | -66.26M | -81.68M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-53.78M | -152.03M | -66.26M | -81.68M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -53.78M | -152.03M | -66.26M | -81.68M |
| Basic EPS from Continuing Ops. | -0.46 | -1.34 | -0.66 | -0.90 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.46 | -1.34 | -0.66 | -0.90 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.46 | -1.34 | -0.66 | -0.90 |
| Basic Normalized Net Income/Share | -0.46 | -1.34 | -0.66 | -0.90 |
| EPS fr Continuing Ops. | -0.46 | -1.34 | -0.66 | -0.90 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.46 | -1.34 | -0.66 | -0.90 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.46 | -1.34 | -0.66 | -0.90 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.46 | -1.34 | -0.66 | -0.90 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with SGEN
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ProColumbia Wanger Asset Manag...
- ContributorEarnings Short Squeeze Play...
- UserOwn Now
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Biotech Stocks Loved and...
Latest SGEN Headlines from TheStreet
- 5 Stocks Poised for Breakouts 04.19.13 | 02:04 pm
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX 04.05.13 | 06:04 am
- Declines From Seattle Genetics Inc. (SGEN) Drive Down Health Care Sector 03.28.13 | 05:03 pm
- 4 Stocks Pushing The Drugs Industry Lower 02.13.13 | 12:02 pm
- 5 Stocks Poised to Pop on Bullish Earnings 02.11.13 | 12:02 pm
- Cramer's Top Stock Picks: IMGN ENG SGEN 12.11.12 | 06:12 am
- Cramer's 'Mad Money' Recap: No Deal = No Good 12.10.12 | 08:12 pm
- Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer 12.10.12 | 07:12 am
- Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancer 12.08.12 | 10:12 am
Press Releases for SGEN
- Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With ADCETRIS® (Brentuximab Vedotin) In Relapsed Hodgkin Lymphoma And Systemic ALCL - Business Wire 03.18.13 | 09:03 am
- Seattle Genetics To Present At Upcoming Investor Conferences - Business Wire 02.27.13 | 09:02 am
- Seattle Genetics Reports Fourth Quarter And Year 2012 Financial Results - Business Wire 02.12.13 | 04:02 pm
- Seattle Genetics Initiates Two Phase I Trials Of SGN-CD19A - Business Wire 02.06.13 | 09:02 am
- Health Canada Approves ADCETRIS® (Brentuximab Vedotin) For The Treatment Of Relapsed Or Refractory Hodgkin Lymphoma (HL) And Systemic Anaplastic Large Cell Lymphoma (sALCL) - Business Wire 02.01.13 | 02:02 pm
- Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2012 Financial Results On February 12, 2013 - Business Wire 01.29.13 | 09:01 am
- Seattle Genetics Announces Data From ASG-5ME Phase I Clinical Trial For Pancreatic Cancer - Business Wire 01.25.13 | 09:01 am
- Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL) - Business Wire 01.24.13 | 09:01 am
- Seattle Genetics To Present At The J.P. Morgan Healthcare Conference - Business Wire 01.03.13 | 09:01 am
- Seattle Genetics Highlights Data Presentations From Genentech ADC Collaborator Programs At ASH Annual Meeting - Business Wire 12.11.12 | 07:12 am
Partner Headlines for SGEN
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Anything Can Happen This Year For Celldex - Seeking Alpha 02.18.13 | 09:02 am
- Show Me The Money: ADC Revenue Payloads Miss The Mark - Seeking Alpha 11.26.12 | 09:11 am
- UPDATE: Credit Suisse Initiates Seattle Genetics at Outperform; Antubody Pure-Play - Benzinga 11.13.12 | 01:11 pm
- Millennium, Seattle Genetics Announce Phase 3 Clinical Trial of ADCETRIS - Benzinga 11.01.12 | 08:11 am
- Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN - NASDAQ 09.10.12 | 02:09 pm
- WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS - NASDAQ 09.03.12 | 02:09 pm
- Armed Antibodies: The Latest Weapon In The War Against Cancer - Seeking Alpha 07.23.12 | 09:07 am
- Healthcare Biz Recap: Affymax On A ROLL, Acadia CRASHES - Wall St. Cheat Sheet 07.15.12 | 11:07 am
- Mid-Cap Biotech Stocks Accumulated By The World's Largest Money Managers - Seeking Alpha 07.13.12 | 06:07 pm
